[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41
1. Sarini J, Bocciolini C, Fournier C, Penel N, Kara A, Van JT, Lefebvre JL: [Induction chemotherapy and larynx preservation: is such practice useful?]. Bull Cancer; 2002 Apr;89(4):411-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy and larynx preservation: is such practice useful?].
  • [Transliterated title] Chimiothérapie d'induction et préservation laryngée qu'en est-il en pratique?
  • BACKGROUND: Surgery followed by irradiation is considered to be the standard treatment but require frequently a total laryngectomy.
  • Chemotherapy followed by irradiation is available in larynx and hypopharynx squamous cell carcinoma (SCC) treatment.
  • Are results obtained in daily induction chemotherapy usefulness identical to results obtained in larynx preservation studies?
  • PATIENTS AND METHOD: We conducted a retrospective study on patients treated at centre Oscar-Lambret, Lille, from 1986 to 1995, by chemotherapy followed by definitive radiotherapy or by surgery and radiotherapy for laryngeal or hypopharyngeal cancer treatment.
  • All patients were naive of previous head and neck SCC and a surgical treatment, requiring total laryngectomy, should be proposed with curative intent.
  • Induction chemotherapy associated cisplatin (100 mg/m2) on day 1 and 5-fluorouracil (5FU)(1,000 mg/m2) on days 1-4 or 1-5.
  • If case of non-responder, patients underwent surgical treatment followed by irradiation.
  • We observed more stage III and less stage IV in group 1.
  • For chemotherapy-related toxic reactions, the exclusive statistical difference observed was haematological toxicity grade III and IV after the second cycle (0 pt in group 1 vs 8 pts in group 2; p =.02).
  • After initial treatment, complete response was achieved without statistical difference between the groups (88.2% vs 78%; p =.27).
  • A surgical procedure was performed in 46 cases without difference according to the reference group and functional larynx preservation was 55.8% (29/52) in group 1 and 53.6% (30/56) in group 2.
  • Cancer was the first cause of death in both groups.
  • Some parameters influenced the overall survival like T (p =.04), response to chemotherapy (p=.006), extra capsular spread (p = 0.03) and response after completion treatment.
  • CONCLUSION: Induction chemotherapy is available for larynx preservation but cannot be considered as a standard treatment.
  • Recent publication, on increase postoperative infection after chemotherapy, should be evaluated in clinical trial.
  • Larynx preservation remains an interesting point of view for patients but stay an optional procedure and not a reference.
  • [MeSH-major] Carcinoma, Squamous Cell. Hypopharyngeal Neoplasms. Laryngeal Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Laryngectomy / methods. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12016041.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Liu WS, Hsin CH, Chou YH, Liu JT, Wu MF, Tseng SW, Lee JK, Tseng HC, Wang TH, Su MC, Lee H: Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation. BMC Cancer; 2010;10:102
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation.
  • BACKGROUND: The objective of this retrospective study is to investigate laryngeal preservation and long-term treatment results in hypopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) combined with chemotherapy.
  • METHODS: Twenty-seven patients with hypopharyngeal carcinoma (stage II-IV) were enrolled and underwent concurrent chemoradiotherapy.
  • The chemotherapy regimens were monthly cisplatin and 5-fluorouracil for six patients and weekly cisplatin for 19 patients.
  • RESULTS: The median follow-up time for survivors was 53.0 months (range 36-82 months).
  • CONCLUSIONS: After long-term follow-up, our results confirmed that patients with hypopharyngeal carcinoma treated with IMRT concurrent with platinum-based chemotherapy attain high functional laryngeal and local-regional control survival rates.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Larynx / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Radiotherapy, Intensity-Modulated / adverse effects. Radiotherapy, Intensity-Modulated / methods. Retrospective Studies

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):195-205 [10656393.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):410-21 [16168834.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):65-71 [10758306.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Int J Cancer. 2001 Apr 20;96(2):126-31 [11291096.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22 [12007936.001]
  • [Cites] Radiother Oncol. 2003 Mar;66(3):253-62 [12742264.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Laryngoscope. 1977 Aug;87(8):1288-303 [881922.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Mar;10(3):357-63 [6423584.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):363-73 [15925451.001]
  • [Cites] Strahlenther Onkol. 2006 Jun;182(6):331-5 [16703288.001]
  • [Cites] Cancer J. 2006 Nov-Dec;12(6):494-500 [17207319.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):459-68 [17493769.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):36-41 [17709149.001]
  • [Cites] Auris Nasus Larynx. 2007 Dec;34(4):499-504 [17604583.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):377-85 [18164838.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 4;101(3):142-52 [19176454.001]
  • [Cites] Acta Otolaryngol. 2009 Mar;129(3):311-7 [18607975.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):146-53 [19553034.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Head Neck. 1996 Sep-Oct;18(5):405-11 [8864731.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • [Cites] Head Neck. 2005 Jan;27(1):15-21 [15515158.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 May;262(5):374-8 [15906056.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):619-30 [10701741.001]
  • (PMID = 20298550.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC3087314
  •  go-up   go-down


3. Rubio Suárez A, Teigeiro Núñez V, Gallo Terán J, Señaris González B, Mesuro Domínguez N: [Induction chemotherapy using vinorelbine, cisplatin, and UFT in advanced pharyngeo-laryngeal carcinomas: results of a phase II study]. Acta Otorrinolaringol Esp; 2003 Dec;54(10):697-703
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy using vinorelbine, cisplatin, and UFT in advanced pharyngeo-laryngeal carcinomas: results of a phase II study].
  • [Transliterated title] Quimioterapia de inducción con vinorelbine, cisplatino y UFT en carcinomas avanzados faringo-laríngeos: resultados de un estudio fase II.
  • OBJECTIVE: To evaluate the results of an induction chemotherapy protocol with Vinorelbine, UFT and Cisplatin (UFTVP).
  • METHODS: 93 patients with laryngo-pharyngeal squamous cell carcinoma in stage III or IV were prospectively entered into a protocol to receive four cycles of UFTVP.
  • Responders followed definitive radiation therapy.
  • RESULTS: Following chemotherapy nodal response (complete in 28% and partial in 33%) was less than that the primary site (complete in 60% and partial in 30%), p = 0.002.
  • Successful larynx preservation was achieved in 50% of patients with laryngeal cancer and in 29% of patients with hypopharyngeal cancer.
  • CONCLUSIONS: UFTVP is an active regime of chemotherapy in advanced squamous cell carcinoma of the pharynx and larynx.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Laryngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / drug therapy. Tegafur / therapeutic use. Uracil / therapeutic use. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Alcohol Drinking / adverse effects. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / mortality. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery. Laryngectomy. Life Tables. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Prospective Studies. Remission Induction. Risk Factors. Smoking / adverse effects. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15164709.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; 1-UFT protocol
  •  go-up   go-down


Advertisement
4. Chang MF, Wang HM, Kang CJ, Huang SF, Lin CY, Fang KH, Chen EY, Chen IH, Liao CT, Chang JT: Treatment results for hypopharyngeal cancer by different treatment strategies and its secondary primary--an experience in Taiwan. Radiat Oncol; 2010;5:91
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results for hypopharyngeal cancer by different treatment strategies and its secondary primary--an experience in Taiwan.
  • PURPOSE: The aim of this study was to evaluate treatment results in our hypopharyngeal cancer patients.
  • PATIENTS AND METHODS: A total of three hundred and ninety five hypopharyngeal cancer patients received radical treatment at our hospital; 96% were male.
  • All patients received a CT scan or MRI for tumor staging before treatment.
  • The stage distribution was stage I: 2 (0.5%); stage II: 22 (5.6%); stage III: 57 (14.4%) and stage IV: 314 (79.5%).
  • Radical surgery was used first in 81 patients (20.5%), and the remaining patients (79.5%) received organ preservation-intended treatment (OPIT).
  • In the OPIT group, 46 patients received radiotherapy alone, 156 patients received chemotherapy followed by radiotherapy (CT/RT) and 112 patients received concomitant chemo-radiotherapy (CCRT).
  • RESULTS: The five-year overall survival rates for stages I/II, III and IV were 49.5%, 47.4% and 18.6%, respectively.
  • Thirty-seven patients developed a second malignancy, with an annual incidence of 4.6%.
  • CONCLUSIONS: There was no survival difference between OPIT and radical surgery in hypopharyngeal cancer patients at our hospital.
  • Additionally, second primary cancers are another important issue for hypopharyngeal cancer management.
  • [MeSH-major] Hypopharyngeal Neoplasms / therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Digestive System Surgical Procedures. Female. Humans. Incidence. Kaplan-Meier Estimate. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Radiotherapy. Taiwan. Tegafur / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6 [10601378.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1391-6 [20056352.001]
  • [Cites] Semin Surg Oncol. 2001 Jan-Feb;20(1):66-74 [11291134.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2001 Feb;26(1):59-61 [11298170.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2989-95 [12115388.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):733-8 [12874074.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):481-7 [15145166.001]
  • [Cites] Head Neck. 2004 Jul;26(7):561-72 [15229898.001]
  • [Cites] ANZ J Surg. 2004 Jul;74(7):554-8 [15230789.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2856-64 [15254053.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):861-7 [15262764.001]
  • [Cites] Onkologie. 2004 Aug;27(4):368-75 [15347892.001]
  • [Cites] Cancer Treat Rev. 1975 Sep;2(3):177-91 [1104162.001]
  • [Cites] Am J Surg. 1977 Oct;134(4):489-91 [911032.001]
  • [Cites] Cancer. 1983 May 15;51(10):1819-25 [6831347.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1685-91 [2317751.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Aug;122(8):853-7 [8703389.001]
  • [Cites] Head Neck. 1996 Sep-Oct;18(5):405-11 [8864731.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Feb;125(2):142-8 [10037279.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • [Cites] Clin Otolaryngol. 2005 Feb;30(1):52-7 [15748191.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):279-86 [16012523.001]
  • [Cites] Br J Cancer. 2005 Nov 14;93(10):1117-21 [16251869.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1064-71 [16505425.001]
  • [Cites] Strahlenther Onkol. 2006 Jun;182(6):331-5 [16703288.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):459-68 [17493769.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • (PMID = 20925962.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin
  • [Other-IDs] NLM/ PMC2958972
  •  go-up   go-down


5. Montero EH, Trufero JM, Romeo JA, Terré FC: Comorbidity and prognosis in advanced hypopharyngeal-laryngeal cancer under combined therapy. Tumori; 2008 Jan-Feb;94(1):24-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbidity and prognosis in advanced hypopharyngeal-laryngeal cancer under combined therapy.
  • AIMS AND BACKGROUND: The success of combined treatment in head and neck cancer resides largely in its completion, which can be compromised when the patient's general health status is precarious.
  • The objective of this investigation was to study the role of comorbidity as a prognostic factor in a large, homogeneous population affected by locally advanced pharyngeal-laryngeal cancer, under a combined protocol treatment.
  • The a priori hypothesis is that comorbidity strongly conditions overall survival and specific overall survival in these patients and can aid in the selection and individualization of treatments.
  • Of the original 114 patients selected, 15 were withdrawn because the tumor spread to maxillofacial areas, or due to the lack of attendance at the clinic, incomplete clinical data or coexistent primary tumors.
  • The group under analysis consisted of the 99 remaining patients affected by stage III and IV laryngeal and/or hypopharyngeal cancers that had not received previous treatments.
  • In the multivariate analysis, tumor staging, neoadjuvant chemotherapy response and comorbidity (RR = 1.55 and 1.44 for overall and specific overall survival, respectively) present themselves as three prognostic factors independent of overall and specific overall survival.
  • CONCLUSIONS: The role of comorbidity as an independent prognostic factor in patients affected by laryngeal and/or hypopharyngeal cancer treated with chemo-radiotherapy should be taken into account in the tailoring of treatments and the improvement of therapeutic results.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Hypopharyngeal Neoplasms / epidemiology. Laryngeal Neoplasms / epidemiology
  • [MeSH-minor] Combined Modality Therapy. Comorbidity. Follow-Up Studies. Humans. Middle Aged. Prognosis. Retrospective Studies. Spain / epidemiology. Survival Rate

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18468331.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Soo KC, Tan EH, Wee J, Lim D, Tai BC, Khoo ML, Goh C, Leong SS, Tan T, Fong KW, Lu P, See A, Machin D: Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer; 2005 Aug 8;93(3):279-86
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison.
  • We compared concurrent combination chemotherapy and radiotherapy with surgery and adjuvant radiotherapy in patients with stage III/IV nonmetastatic squamous cell head and neck cancer.
  • Patients with non-nasopharyngeal and nonsalivary resectable squamous cell head and neck cancer were randomised to receive either surgery followed by adjuvant radiotherapy (60 Gy over 30 fractions) or concurrent combination chemotherapy and radiotherapy (66 Gy in 33 fractions).
  • Combination chemotherapy comprised two cycles of i.v. cisplatin 20 mg m(-2) day(-1) and i.v.
  • Those with laryngeal/hypopharyngeal disease subsite had a higher organ-preservation rate than the rest (68 vs 30%).
  • Combination chemotherapy and concurrent irradiation with salvage surgery was not superior to conventional surgery and postoperative radiotherapy for resectable advanced squamous cell head and neck cancer.
  • However, this form of treatment schedule with a view to organ-preservation can be attempted especially for those with laryngeal/hypopharyngeal and possibly oropharyngeal disease subsites.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Otorhinolaryngologic Surgical Procedures. Radiotherapy, Adjuvant
  • [MeSH-minor] Adult. Aged. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):876-83 [10679658.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] Head Neck. 1997 Oct;19(7):567-75 [9323144.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2136-42 [8229127.001]
  • [Cites] Am J Clin Oncol. 1994 Oct;17(5):369-73 [8092105.001]
  • [CommentIn] Br J Cancer. 2006 May 22;94(10):1544-5; author reply 1546-7 [16705316.001]
  • (PMID = 16012523.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361563
  •  go-up   go-down


7. Krstevska V, Stojkovski I, Lukarski D: Concurrent radiochemotherapy in advanced hypopharyngeal cancer. Radiat Oncol; 2010;5:39
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent radiochemotherapy in advanced hypopharyngeal cancer.
  • Unfortunately, there is a lack of level one evidence on best treatment approach for advanced hypopharyngeal cancer.
  • This report aims to summarize the results of our study on concurrent radiochemotherapy in patients with advanced hypopharyngeal cancer.
  • METHODS: A retrospective analysis of 41 patients with stage III-IV hypopharyngeal cancer was performed.
  • All patients were treated with three dimensional conformal radiotherapy and received 70 Gy in 35 fractions (2 Gy per fraction, 5 fractions per week).
  • In dependence of the period when radiotherapy was realized, two different treatment techniques were used.
  • Concurrent chemotherapy consisted of cisplatin 30 mg/m2 given on a weekly basis.
  • Stage IV disease was recognized in 73.2% of the patients.
  • Complete response rates at the primary site and at the metastatic neck lymph nodes were 68.3% and 36.6%, respectively.
  • Confluent mucositis was developed in 46.3% of patients.
  • The median weight loss at the end of treatment was 12% (range 5-21).
  • The worst grade of late toxicity was most commonly pronounced in the skin and in the subcutaneous tissue.
  • CONCLUSIONS: Based on unsatisfactory results in our study we suggest that the use of sequential radiochemotherapy or chemotherapy given concomitantly with altered fractionation radiotherapy with the implementation of intensity-modulated radiotherapy as radiotherapy technique could represent treatment approaches able to improve outcome in patients with advanced hypopharyngeal cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1458-64 [10735893.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Sep;124(9):951-62 [9738803.001]
  • [Cites] Radiother Oncol. 2000 May;55(2):101-10 [10799721.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16 [10924966.001]
  • [Cites] Acta Oncol. 2000;39(4):529-36 [11041117.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2001 Feb;26(1):59-61 [11298170.001]
  • [Cites] Head Neck. 2001 Sep;23(9):713-7 [11505479.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2002 Oct;27(5):413-20 [12383309.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):320-6 [12525525.001]
  • [Cites] Lancet. 2003 Sep 20;362(9388):933-40 [14511925.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3540-8 [15337803.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Cancer. 1983 May 15;51(10):1819-25 [6831347.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Mar;11(3):499-504 [3972662.001]
  • [Cites] Laryngoscope. 1987 Aug;97(8 Pt 1):901-4 [3613786.001]
  • [Cites] Head Neck. 1993 Sep-Oct;15(5):405-12 [8407312.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4665-73 [15534360.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1125-35 [15718308.001]
  • [Cites] Clin Otolaryngol. 2005 Feb;30(1):52-7 [15748191.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] BMC Cancer. 2006;6:28 [16448551.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1064-71 [16505425.001]
  • [Cites] Lancet. 2006 Sep 2;368(9538):843-54 [16950362.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):459-68 [17493769.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):156-70 [17482300.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):7-16 [17920715.001]
  • [Cites] Acta Otolaryngol. 2008 May;128(5):590-6 [18421617.001]
  • [Cites] Jpn J Clin Oncol. 2008 Aug;38(8):521-7 [18697758.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1143-54 [18784104.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 4;101(3):142-52 [19176454.001]
  • [Cites] Acta Oncol. 2009;48(4):541-48 [18979267.001]
  • [Cites] Head Neck. 2009 Jun;31(6):748-58 [19189340.001]
  • [Cites] Radiother Oncol. 2009 Jul;92(1):4-14 [19446902.001]
  • [Cites] Cancer. 2009 Dec 15;115(24):5711-22 [19708030.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):21-8 [19897418.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1995 Jun;20(3):249-53 [7554339.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Laryngoscope. 1997 May;107(5):648-53 [9149168.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1318-24 [9552032.001]
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • (PMID = 20482772.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2890021
  •  go-up   go-down


8. Yang L, Chen WK, Guo ZM, Gu MF, Huang HQ, Zhang Q, Yang AK: Long-term survival of induction chemotherapy plus surgery and postoperative radiotherapy in patients with stage IV hypopharyngeal cancer. Anticancer Drugs; 2010 Oct;21(9):872-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of induction chemotherapy plus surgery and postoperative radiotherapy in patients with stage IV hypopharyngeal cancer.
  • This study was conducted to evaluate the safety, efficacy, and tolerability of induction chemotherapy plus surgery and postoperative radiotherapy in patients with stage IV hypopharyngeal cancer.
  • The patients received two to three cycles of induction chemotherapy before surgery, with cisplatin (100 mg/m(2)) by rapid intravenous (i.v.) infusion over 15-20 min on day 1, bleomycin (10 mg/m(2)) on days 1 and 5, and 5-fluorouracil (800 mg/m(2)/day) by continuous i.v. infusion on days 1 through 5, repeated every 21 days.
  • After completion of two to three courses of induction chemotherapy, 22 cases of CR (complete response) and 16 cases of PR (partial response) in the primary site were confirmed, giving an overall response rate (ORR) of 73.1% [95% confidence interval (CI), 61.1-85.2%].
  • The combined primary tumor site and lymph node response was 17 CRs and 16 PRs, giving an ORR of 63.5% (95% CI, 50.4-76.6%).
  • The median time to progression and overall survival for all the patients were 32 months (95% CI, 7.6-56.4 months) and 36 months (95% CI, 22.3-49.7 months), respectively.
  • The estimate of time to progression and overall survival at 5 years was 24.5% (95% CI, 12.5-36.5%) and 35.9% (95% CI, 23.2-48.6%), respectively.
  • In conclusion, induction chemotherapy plus surgery and postoperative radiotherapy is a treatment modality that is tolerated with encouraging activity and survival outcome in patients with stage IV hypopharyngeal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hypopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Combined Modality Therapy. Disease Progression. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant / methods. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20836197.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Lee NY, O'Meara W, Chan K, Della-Bianca C, Mechalakos JG, Zhung J, Wolden SL, Narayana A, Kraus D, Shah JP, Pfister DG: Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys; 2007 Oct 1;69(2):459-68
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers.
  • PURPOSE: To perform a retrospective review of laryngeal/hypopharyngeal carcinomas treated with concurrent chemotherapy and intensity-modulated radiotherapy (IMRT).
  • METHODS AND MATERIALS: Between January 2002 and June 2005, 20 laryngeal and 11 hypopharyngeal carcinoma patients underwent IMRT with concurrent platinum-based chemotherapy; most patients had Stage IV disease.
  • The prescription of the planning target volume for gross, high-risk, and low-risk subclinical disease was 70, 59.4, and 54 Gy, respectively.
  • Grade 2 mucositis or higher occurred in 48% of patients, and all experienced Grade 2 or higher pharyngitis during treatment.
  • Xerostomia continued to decrease over time from the end of RT, with none complaining of Grade 2 toxicity at this analysis.
  • The 2-year post-treatment percutaneous endoscopic gastrostomy-dependency rate for those with hypopharyngeal and laryngeal tumors was 31% and 15%, respectively.
  • CONCLUSION: These preliminary results have shown that IMRT achieved encouraging locoregional control of locoregionally advanced laryngeal and hypopharyngeal carcinomas.
  • Xerostomia improved over time.
  • Pharyngoesophageal stricture with percutaneous endoscopic gastrostomy dependency remains a problem, particularly for patients with hypopharyngeal carcinoma and, to a lesser extent, those with laryngeal cancer.
  • [MeSH-major] Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy / methods. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Survival Rate

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493769.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Saussez S, Cucu DR, Decaestecker C, Chevalier D, Kaltner H, André S, Wacreniez A, Toubeau G, Camby I, Gabius HJ, Kiss R: Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol; 2006 Jul;13(7):999-1009
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer.
  • BACKGROUND: Eighty percent of hypopharyngeal squamous cell carcinoma patients have advanced stages (III and IV) of the disease, and biological markers are required to predict high-risk head and neck squamous cell carcinoma patients in need of highly aggressive treatments after surgery to improve the survival rate.
  • We analyzed the potential prognostic value of galectin 7 in a series of 81 stage IV hypopharyngeal SCCs because galectin 7 is an emerging marker involved in the epidermal development of pluristratified epithelia and in epidermal cell migration.
  • METHODS: The immunohistochemical expression of galectin 7 was determined on a series of 81 stage IV hypopharyngeal SCCs and was compared with that of galectins 1 and 3.
  • RESULTS: High levels of galectin 7 expression were associated with rapid recurrence rates and dismal prognoses in these 81 stage IV hypopharyngeal SCCs, a feature not observed with galectin 3 and one observed weakly, if at all, with galectin 1.
  • CONCLUSIONS: These data suggest that the immunohistochemical determination of galectin 7 expression in the case of high-risk hypopharyngeal cancers is a meaningful tool to identify patients who should benefit from aggressive postsurgical adjuvant therapy after surgery, including not only radiotherapy, but also chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Galectins / metabolism. Hypopharyngeal Neoplasms / metabolism. Hypopharyngeal Neoplasms / mortality. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Female. Galectin 3 / metabolism. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16788763.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / Galectins; 0 / LGALS7 protein, human
  •  go-up   go-down


11. Tsukuda M, Kida A, Fujii M, Kono N, Yoshihara T, Hasegawa Y, Sugita M: [Long-term results of S-1 administration as adjuvant chemotherapy for advanced head and neck cancer]. Gan To Kagaku Ryoho; 2007 Aug;34(8):1215-25
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of S-1 administration as adjuvant chemotherapy for advanced head and neck cancer].
  • The long-term results of a multi-institutional study were analyzed in 101 cases (27 with stage III and 74 with stage IV) with advanced head and neck squamous cell carcinoma (HNSCC) given S-1 administration for 6 months after definitive treatments.
  • The relapse rate increased according to the advancement of N staging and the higher risk of distant metastasis in cases with laryngeal (especially, supraglottic type) or hypopharyngeal carcinomas.
  • Now, the efficacy of S-1 administration as adjuvant chemotherapy after definitive treatments for advanced HNSCC is under investigation,and the adequate administration period of S-1 should be evaluated in a controlled randomized study in future.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Disease-Free Survival. Drug Administration Schedule. Drug Combinations. Humans. Neoplasm Recurrence, Local / etiology. Prognosis. Proportional Hazards Models. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687202.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


12. Wang HM, Hsueh CT, Wang CS, Chen IH, Liao CT, Tsai MH, Yeh SP, Chang JT: Phase II trial of cisplatin, tegafur plus uracil and leucovorin as neoadjuvant chemotherapy in patients with squamous cell carcinoma of the oropharynx and hypopharynx. Anticancer Drugs; 2005 Apr;16(4):447-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of cisplatin, tegafur plus uracil and leucovorin as neoadjuvant chemotherapy in patients with squamous cell carcinoma of the oropharynx and hypopharynx.
  • We evaluated the efficacy and toxicity of cisplatin, tegafur plus uracil and leucovorin as neoadjuvant chemotherapy for locally advanced squamous cell carcinoma (SCC) of the oropharynx and hypopharynx.
  • Forty-six patients (stage IV, 83%; N2/3, 52%) were treated with PUL (50 mg/m2 cisplatin on day 1, 300 mg/m2 tegafur plus uracil orally and 60 mg leucovorin orally on days 1-14) over a 14-day cycle.
  • Evaluation after 3 cycles led to chemotherapy termination if primary tumor responses were less than partial responses.
  • Otherwise, PUL was continued up to 6 cycles before locoregional therapy.
  • Patients achieving at least good partial responses at the primary site after neoadjuvant chemotherapy received radiotherapy for organ preservation.
  • Chemotherapy responses were analyzed by intent-to-treat.
  • We concluded that the outpatient PUL regimen was a moderately effective, less-toxic neoadjuvant chemotherapy for SCC of the oropharynx and hypopharynx.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Neoadjuvant Therapy. Oropharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Female. Humans. Leucovorin / administration & dosage. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Survival Rate. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746582.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin
  •  go-up   go-down


13. Magné N, Marcy PY, Chamorey E, Guardiola E, Pivot X, Schneider M, Demard F, Bensadoun RJ: Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients: A long-term quality of life analysis. Head Neck; 2001 Aug;23(8):678-82
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients: A long-term quality of life analysis.
  • This study is based upon a French quality of life (QoL) questionnaire in a cohort of advanced head and neck (H&N) cancer patients treated by concomitant twice-a-day continuous radiotherapy with no acceleration and chemotherapy with cisplatin and 5-fluorouracil.
  • All patients had stage IV strictly unresectable squamous cell carcinoma of oropharynx or hypopharynx.
  • A French specific H&N cancer QoL questionnaire was used at the end of radiotherapy and at the last date of follow-up of each patient (during 1999).
  • p values reflect comparison of percentages obtained at the end of treatment with percentages at long-term follow-up.
  • Acute treatment toxicities were severe with declines in virtually all QoL and functional domains.
  • Globally, with an average long-term follow-up of 4.5 years (range 3-7 years after treatment), there is a statistical improvement in the following symptoms: dry mouth and sticky saliva (97% versus 55%, p <.05); tasting problems (35% versus 21%, not significant); swallowing problems (77% versus 36%, p <.05); and H&N pain (86% versus 9%, p <.05).
  • Fourteen of 29 (48%) patients were drinking and 8 of 29 (28%) were smoking at long-term follow-up; at the diagnosis they were 86% and 90%, respectively.
  • CONCLUSION: The interest of twice-a-day radiotherapy with concomitant chemotherapy is to increase total radiotherapy equivalent dose without increasing late toxicity and also to improve locoregional control, survival, and long-term QoL/effectiveness ratio.
  • Best supportive care is recommended to obtain both good QoL and cancer control in a long-term follow-up.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Quality of Life
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Enteral Nutrition. Female. Fluorouracil / therapeutic use. Gastrostomy. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11443751.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, Flentje M, Eckel HE, Mueller RP: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1161-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
  • PURPOSE: To demonstrate the efficacy of radiochemotherapy (RCT) as the first choice of treatment for advanced unresectable head-and-neck cancer.
  • To prove an expected benefit of simultaneously given chemotherapy, a two-arm randomized study with hyperfractionated accelerated radiochemotherapy (HF-ACC-RCT) vs. hyperfractionated accelerated radiotherapy (HF-ACC-RT) was initiated.
  • METHODS AND MATERIALS: Patients with Stage III and IV (UICC) unresectable oro- and hypopharyngeal carcinomas were randomized for HF-ACC-RCT with 2 cycles of 5-FU (600 mg/m(2)/day)/carboplatinum (70 mg/m(2)) on days 1--5 and 29--33 (arm A) or HF-ACC-RT alone (arm B).
  • Total RT dose in both arms was 69.9 Gy in 38 days, with a concomitant boost regimen (weeks 1--3: 1.8 Gy/day, weeks 4 and 5: b.i.d.
  • RT with 1.8 Gy/1.5 Gy).
  • Between July 1995 and May 1999, 263 patients were randomized (median age 56 years; 96% Stage IV tumors, 4% Stage III tumors).
  • RESULTS: This analysis is based on 240 patients: 113 patients with RCT and 127 patients with RT, qualified for protocol and starting treatment.
  • There were 178 oropharyngeal and 62 hypopharyngeal carcinomas.
  • Treatment was tolerable in both arms, with a higher mucosal toxicity after RCT.
  • After a median observed time of 22.3 months, l- and 2-year local-regional control (LRC) rates were 69% and 51% after RCT and 58% and 45% after RT (p = 0.14).
  • Patients with oropharyngeal carcinomas showed significantly better SLC after RCT (60%) vs. RT (40%, p = 0.01); the smaller group of hypopharyngeal carcinomas had no statistical benefit of RCT (p = 0.84).
  • For both tumor locations, prophylactically given G-CSF was a poor prognostic factor (Cox regression), and resulted in reduced LRC (log-rank test: +/- G-CSF, p = 0.0072).
  • CONCLUSION: With accelerated radiotherapy, the efficiency of simultaneously given chemotherapy may be not as high as expected when compared to standard fractionated RT.
  • Oropharyngeal carcinomas showed better LRC after HF-ACC-RCT vs. HF-ACC-RT; hypopharyngeal carcinomas did not.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Dose Fractionation. Head and Neck Neoplasms / radiotherapy. Radiotherapy, High-Energy / methods
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Germany / epidemiology. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / mortality. Hypopharyngeal Neoplasms / radiotherapy. Life Tables. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / radiotherapy. Prognosis. Proportional Hazards Models. Prospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):300 [12183004.001]
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1423; author reply 1423-4 [11955758.001]
  • [ErratumIn] Int J Radiat Oncol Biol Phys 2001 Oct 1;51(2):569
  • (PMID = 11483325.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Hasegawa Y, Hanai N, Terada A, Ozawa T, Goto M: Orotate phosphoribosyl transferase and XPA expressions as predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers. J Clin Oncol; 2009 May 20;27(15_suppl):6084

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orotate phosphoribosyl transferase and XPA expressions as predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers.
  • : 6084 Background: The main purpose of the present study was to find predictive biomarkers that can be routinely used for the response to chemotherapy in head and neck squamous cell carcinomas.
  • METHODS: Sixty-four tumor specimens from patients undergoing radical treatment for squamous cell carcinomas of the oro- and hypopharynx in stage II, III, or IV, were included in the present study.
  • There were 30 primary tumors sites in the oropharynx and 34 in the hypopharynx, respectively.
  • All patients were administered induction chemotherapy (FP) with a combination of 5-FU (800 (600) mg/m<sup>2</sup> d1-5 (6)) and cisplatin (80 mg/m<sup>2</sup> d6 (7)) before definitive therapy.
  • This chemotherapy was used in order to select patients for organ preservation based on the response and decrease in late salvage surgery rate.
  • Treatment was repeated every 3 to 4 weeks.
  • Using biopsy specimens, we analyzed their gene expression profiles with the following 25 markers, which we thought were likely predictors of the response to anti-cancer agents: TS, DPD, OPRT, TP, COX2, MDR1, MRP1, VEGF, EGFR, HER2, PIK3CA, PTEN, p53, Rb1, Bcl2, BclX, BAX, GSTπ, ERCC1, XPA, E2F1, ENT1, Rev3, β-tubulin, and Survivin.
  • These mRNA expressions were quantified by real-time reverse transcription polymerase chain reaction (real-time RT-PCR) assay.
  • RESULTS: Univariately, response for chemotherapy was significantly correlated with T factor (p = 0.015), and the mRNA expression level of XPA (p = 0.018) and OPRT (p = 0.047).
  • Meanwhile, using a multivariate logistic regression analysis with these factors (clinical markers, OPRT and XPA), T factor (p = 0.048) and the expression of XPA (p = 0.035) were demonstrated to be independent predictors for chemotherapy.
  • CONCLUSIONS: XPA (Xeroderma Pigmentosum A) and OPRT (Orotate phosphoribosyl transferase) may be possible reliable predictive biomarkers for FP therapy, and might help the decision-making strategy for individual patients with head and neck cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961950.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Lefebvre JL, Chevalier D, Luboinski B, Traissac L, Andry G, De Raucourt D, Collette L, Bernier J, EORTC Head and Neck Cancer Cooperative Group: Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):5531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial.
  • : 5531 Background: In 1986, the EORTC HNCCG initiated a randomized phase III trial to assess whether LP using ICT followed by radiation therapy (XRT) was as safe as the conventional treatment: total laryngectomy with partial pharyngectomy (TLP), radical neck dissection (RND) and postop XRT.
  • METHODS: 202 patients (pts) candidates for TLP + RND + XRT were randomly assigned to receive in the surgery arm (arm 1) this treatment or in the ICT arm (arm 2) up to 3 cycles of CDDP (100mg/m<sup>2</sup> day 1) and 5FU (1000 mg/m<sup>2</sup> days 1-5) followed in case of complete response by XRT or by TPL + RND + XRT in the other cases.
  • Stage II, III and IV respectively numbered 6, 51 and 37 in arm 1 and 7, 59 and 34 in arm 2.
  • The hypopharynx SCC evolution was the cause of death in 43 pts in arm 1 and in 41 pts in arm 2.
  • This LP strategy provided similar survival curves as compared with conventional treatment and allowed 2/3 of the survivors to retain their larynx.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Lau H, Yee D, Mackinnon J, Brar S, Hao D, Gluck S: Concomitant low-dose cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN): Analysis of survival and toxicity. J Clin Oncol; 2004 Jul 15;22(14_suppl):5555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From July 2000 to April 2003, 57 patients with locally advanced SCCHN were treated with a regimen of 3D conformal RT, 70 Gy over 7 weeks with concurrent cisplatin 20 mg/M<sup>2</sup> during days 1 - 4 of weeks one and five.
  • Eligible patients included stage II oropharyngeal (4), stage III (12), and stage IV (34) oropharyngeal, hypopharyngeal, and laryngeal SCC cancers.
  • Patients were evaluated by surgeon, radiation oncologist, and medical oncologist prior to treatment.
  • Acute toxicities were graded weekly during treatment and in follow-up according to the RTOG / CTC toxicity criteria.
  • All completed the prescribed radiation dose of 70 Gy.
  • Chemotherapy compliance was as follows: 31 patients (54%) completed 100% of chemotherapy and the remainder completed >= 50% of chemotherapy.
  • Treatment Toxicity: 27/57 (47%) of patients required hospitalization during treatment for supportive care.
  • CONCLUSIONS: This regimen appears tolerable and adds minimal excess toxicity compared to treatment with radiation alone.
  • Our results are comparable to concurrent chemotherapy regimens using either high-dose cisplatin or multiagent chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013971.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Karasawa K, Umezawa T, Hanyu N, Kawamura H, Kiguchi Y, Mitsuhashi T, Niibe Y: Hyperfractionated radiation therapy for the treatment of squamous cell carcinoma of the head and neck. J Clin Oncol; 2004 Jul 15;22(14_suppl):5554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated radiation therapy for the treatment of squamous cell carcinoma of the head and neck.
  • : 5554 Background: Altered fractionation radiation therapy has been thought to improve the local control and survival of the patients with head and neck cancer.
  • Since 1996, we have been conducting a clinical trial of hyperfractionated radiation therapy (HFRT) for the treatment of squamous cell carcinoma of the head and neck (SCCHN).
  • Primary site: Larynx 34 cases, hypopharynx 27 cases, oropharynx 17 cases, oral cavity 5 cases, nasopharynx 4 cases, and maxillary sinus 2 cases.
  • Stage I/II/III/IV(M0) = 11/32/15/31.
  • Chemotherapy was combined in 22 cases.
  • OS and LC of stage I-II and III-IV were, 82.7%, 95.2%, and 54.5%, 53.5%, respectively.
  • As for larynx, OS and LC of overall, stage I-II, and stage III-IV were, 91.2%, 84.2%, 100%, 93.8%, and 50% (2y), 67% (1y), respectively.
  • As for oropharynx, OS and LC of overall, stage I-II, and stage III-IV were, 71.1%, 83.9%, 100% (2y), 100% (2y), and 73.8%, 80%, respectively.
  • As for hypopharynx, OS and LC of overall, stage I-II, and stage III-IV were, 49.9%, 65.3%, 53.6%, 100%, and 48.2%, 42.9%, respectively.
  • Disease-specific survival of stage I-II hypopharyngeal cancer was 100%.
  • CONCLUSIONS: HFRT for SCCHN was promising not only for stage III and IV(advanced) cases but also for stage I and II (early) cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013972.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Semrau R, Mueller RP, Stuetzer H, Staar S, Schroeder U, Guntinas-Lichius O, Kocher M, Eich HT, Dietz A, Flentje M, Rudat V, Volling P, Schroeder M, Eckel HE: Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys; 2006 Apr 1;64(5):1308-16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer.
  • PATIENTS AND METHODS: The study included primarily untreated Stage III/IV (International Union Against Cancer [UICC]) oropharyngeal and hypopharyngeal carcinomas.
  • Total RT dose in both arms was 69.9 Gy in 38 days in concomitant boost technique.
  • RESULTS: After a median follow-up time of 57 months, SLC is significantly better in RCT than in RT (p = 0.01), with median SLC of 17 months and 11 months, respectively.
  • However, the benefit in SLC and OS is not seen in hypopharyngeal carcinomas.
  • In a multivariate analysis of oropharyngeal cancer patients, p-Hb levels lower than 12.7 g/dL resulted in lower SLC compared with higher p-Hb levels up to 13.8 g/dL.
  • [MeSH-major] Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy / methods. Dose Fractionation. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Granulocyte Colony-Stimulating Factor / therapeutic use. Hemoglobin A / analysis. Humans. Male. Middle Aged. Prognosis. Regression Analysis. Survival Analysis. Treatment Outcome

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16464538.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 9034-51-9 / Hemoglobin A; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Yu F, Dong YL, Zu ZJ, Zhan XD, Shu JH, Yang JS, Han GS, Lu LC, Zhang K, Sun HJ, Ren KJ: [Surgical management of hypopharyngeal cancer]. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Aug;38(4):295-9
Genetic Alliance. consumer health - Hypopharyngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical management of hypopharyngeal cancer].
  • OBJECTIVE: To investigate the preservation of laryngeal function for the patients with hypopharyngeal cancer.
  • METHODS: Two hundred and ninety-three cases of hypopharyngeal cancer with surgical management were reviewed retrospectively, and 222 cases were originated from pyriform sinus, 13 from post-cricoid, and 21 from posterior pharyngeal wall.
  • Radiotherapy (37 cases), operation only (56 cases) and the combined treatment (operation plus radiation or chemotherapy, 200 cases) were adopted.
  • RESULTS: The 5 year survival rates of patient with laryngeal function preserved and no laryngeal function preserved were 51.3%, 47.6% (for stage III); 40.4%, 43.3% (for stage IV), respectively.
  • The analysis of survival rates revealed a significant difference between combined therapy and radiotherapy.
  • Conservation laryngectomy improves the quality of patient's life, and combined therapy is the best choice for hypopharyngeal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Hypopharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngectomy. Larynx / physiopathology. Larynx / surgery. Male. Middle Aged. Quality of Life. Reconstructive Surgical Procedures. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14743643.001).
  • [ISSN] 0412-3948
  • [Journal-full-title] Zhonghua er bi yan hou ke za zhi
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Ozer E, Grecula JC, Agrawal A, Rhoades CA, Schuller DE: Intensification regimen for advanced-stage resectable hypopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg; 2006 Apr;132(4):385-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensification regimen for advanced-stage resectable hypopharyngeal carcinoma.
  • OBJECTIVE: To determine feasibility, compliance, long-term survival, and disease control rates in the intensification regimen for advanced resectable hypopharyngeal carcinoma.
  • SETTING: Cancer center at a state university.
  • PATIENTS: Thirty-two patients (age range, 44-79 years; median age, 59 years) with advanced (69% stage IV, 31% stage III) resectable hypopharyngeal carcinoma.
  • INTERVENTIONS: Combination of surgery, radiation therapy, and chemotherapy (cisplatin and paclitaxel) along with intraoperative radiation therapy.
  • CONCLUSIONS: The intensification regimen described in this study accomplished excellent long-term survival and disease control rates in patients with advanced resectable hypopharyngeal carcinoma.
  • [MeSH-major] Hypopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Feasibility Studies. Female. Humans. Laryngectomy. Male. Middle Aged. Ohio / epidemiology. Paclitaxel / administration & dosage. Patient Compliance. Prospective Studies. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618907.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA16058
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Hirano S, Tateya I, Kitamura M, Kada S, Ishikawa S, Kanda T, Tanaka S, Ito J: Ten years single institutional experience of treatment for advanced hypopharyngeal cancer in Kyoto University. Acta Otolaryngol Suppl; 2010 Nov;(563):56-61
Genetic Alliance. consumer health - TEN.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten years single institutional experience of treatment for advanced hypopharyngeal cancer in Kyoto University.
  • CONCLUSION: Treatment of advanced hypopharyngeal cancer has become more conservative and more multidisciplinary, and the prognosis has been improved.
  • Induction chemotherapy has the potential to extend organ preservation therapy even in cases with locally advanced primary lesion.
  • OBJECTIVES: To update the therapeutic outcome of advanced hypopharyngeal cancer.
  • METHODS: A total of 72 cases with stage III/IV hypopharyngeal cancer were treated at Kyoto University Hospital during 2000-2008.
  • Radiotherapy (RT) with or without concurrent chemotherapy was applied in 16 cases.
  • Induction chemotherapy (ICT) has been applied for 14 cases since 2006 to achieve organ preservation and reduction of distant metastasis.
  • Therapeutic outcomes were chart reviewed.
  • [MeSH-major] Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Combined Modality Therapy. Female. Hospitals, University. Humans. Japan. Male. Middle Aged. Neoplasm Staging. Pharyngectomy. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20879820.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Tai SK, Yang MH, Wang LW, Tsai TL, Chu PY, Wang YF, Huang JL, Chang SY: Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer. Jpn J Clin Oncol; 2008 Aug;38(8):521-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer.
  • OBJECTIVE: Laryngeal preservation is a challenge for the treatment of advanced hypopharyngeal cancer.
  • The objective of this study is to evaluate the results of chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer at a single institute and the impact of treatment factors on prognosis.
  • METHODS: The study population consisted of 42 consecutive patients with resectable stage III-IV hypopharyngeal cancer.
  • Patients with T4b tumor, synchronous primary cancer or those treated palliatively were excluded.
  • Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) was performed in 32 (76.2%) patients, whereas primary CCRT was done in the other 10 (23.8%).
  • Patients were grouped according to the dose intensity of chemotherapy and total dose of radiotherapy (RT).
  • CONCLUSIONS: Achievement of optimum treatment dose remains challenging in chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer.
  • The criteria for selecting patients who will respond to and complete the treatment remain key issues for future investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Hypopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Larynx / pathology. Male. Methotrexate / administration & dosage. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome. X-Rays

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Genetic Alliance. consumer health - Laryngeal cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697758.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


24. Akisada T, Harada T, Takemoto T, Fukuda K, Morita N, Aihara T, Kajihara Y, Imai S, Gyoten M, Imajo Y, Hiratsuka J: [A case of advanced hypopharyngeal carcinoma successfully treated with superselective intra-arterial infusion of docetaxel]. Gan To Kagaku Ryoho; 2002 Feb;29(2):323-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced hypopharyngeal carcinoma successfully treated with superselective intra-arterial infusion of docetaxel].
  • Docetaxel is an excellent agent with a high antitumor effect for advanced/recurrent head and neck cancer.
  • A 67-year-old male with advanced hypopharyngeal cancer (T3N2bM1: Stage IV) underwent two courses of superselective intra-arterial infusion of docetaxel and intravenous administration of CDDP and 5-FU.
  • During chemotherapy the patient received concomitant radiotherapy (50 Gy).
  • MRI after chemoradiation showed a complete response for the primary tumor and a partial response for the neck metastasis.
  • We conclude that this superselective intra-arterial infusion of docetaxel will be useful and safe for head and neck cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11865643.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


25. Hirano S, Tateya I, Kitamura M, Kada S, Ishikawa S, Kanda T, Tanaka S, Ito J: Organ preservation surgery for advanced hypopharyngeal cancer. Acta Otolaryngol Suppl; 2010 Nov;(563):50-5
Genetic Alliance. consumer health - Hypopharyngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation surgery for advanced hypopharyngeal cancer.
  • CONCLUSION: Organ preservation surgery with partial pharyngectomy preserving the larynx is feasible for the treatment of advanced hypopharyngeal cancer with comparable local control and preservation of function.
  • OBJECTIVES: To examine the feasibility and therapeutic effects of organ preservation surgery for advanced hypopharyngeal cancer.
  • METHODS: Fourteen patients with stage III/IV hypopharyngeal cancer were treated by partial pharyngectomy with or without partial laryngectomy to preserve the larynx.
  • Induction chemotherapy was administered for six cases including three with T3/4 tumors.
  • [MeSH-major] Hypopharyngeal Neoplasms / therapy. Pharyngectomy
  • [MeSH-minor] Aged. Cohort Studies. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neck Dissection. Neoplasm Staging. Retrospective Studies. Surgical Flaps. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20879819.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Major MS, Bumpous JM, Flynn MB, Schill K: Quality of life after treatment for advanced laryngeal and hypopharyngeal cancer. Laryngoscope; 2001 Aug;111(8):1379-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life after treatment for advanced laryngeal and hypopharyngeal cancer.
  • OBJECTIVES: To compare health-related quality of life measures after treatment for advanced (stages III and IV) laryngeal and hypopharyngeal cancers.
  • METHODS: Our study included 54 patients identified from the Tumor Registry of the University of Louisville Brown Cancer Center who were diagnosed and treated between 1995 and 2000.
  • Demographics, tumor data, and treatment information were obtained from the Tumor Registry database.
  • RESULTS: Fifteen patients were treated with chemotherapy and radiation therapy (CRT).
  • Six patients underwent surgery with postoperative radiation therapy (SRT).
  • The remaining three patients were treated with radiation therapy but were not used in this analysis.
  • The average follow-up was 35 months after treatment.
  • The CRT and SRT groups were statistically similar regarding age, sex, duration of follow-up, tumor grade, and tumor stage.
  • CONCLUSIONS: These results indicate that only one of eight domains differs significantly between treatment groups when using the HSQ-12.
  • Two-year survival end-point analysis of global health assessment may represent a simplified and meaningful way to compare treatment modalities in patients with advanced-stage head and neck cancer.
  • [MeSH-major] Health Status Indicators. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / therapy. Quality of Life
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11568572.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Mochiki M, Sugasawa M, Nibu K, Asai M, Nakao K, Asakage T: Prognostic factors for hypopharyngeal cancer: a univariate and multivariate study of 142 cases. Acta Otolaryngol Suppl; 2007 Dec;(559):136-44
Genetic Alliance. consumer health - Hypopharyngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for hypopharyngeal cancer: a univariate and multivariate study of 142 cases.
  • Effective adjuvant chemotherapy should be developed for patients with advanced primary disease (T>2) as well as for patients with advanced nodal status (N>0 or PLN>2).
  • OBJECTIVES: The aim of this study was to identify prognostic factors for hypopharyngeal cancer.
  • PATIENTS AND METHODS: In all, 142 previously untreated patients were analyzed retrospectively; 75% of the cases were stage III or IV.
  • Surgical resection was administered as primary treatment to 116 of the patients (82%), while 26 patients (18%) underwent primary radiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Hypopharyngeal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pharyngectomy. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18340585.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


28. Beckmann GK, Hoppe F, Pfreundner L, Flentje MP: Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck; 2005 Jan;27(1):36-43
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer.
  • BACKGROUND: The purpose of this study was to determine the feasibility and efficacy of hyperfractionated accelerated radiotherapy (HFRCB) combined with simultaneous chemotherapy with weekly cisplatin (CDDP) in locally advanced inoperable head and neck cancer.
  • METHODS: From August 1999 to December 2002, 37 patients (median age, 59 years) with Union Internationale Contre le Cancer stage III (n = 2) and stage IV (n = 35) squamous cell cancer of the oropharynx and hypopharynx were treated in a prospective phase I/II trial.
  • Concomitant boost radiotherapy (1.8 Gy, days 1-38 and 1.5 Gy boost, days 22-38, twice daily with at least a 6-hour interval; total dose 69.9 Gy) and simultaneous cisplatin, 40 mg/m2 weekly, were given.
  • RESULTS: The median treatment duration was 42 days (range, 38-46 days).
  • Toxicity was manageable, with neutropenia grade III/IV and thrombocytopenia grade IV in seven and one patients, and mucositis grade III/ IV in 27 and five patients, respectively.
  • Chemotherapy was restricted to four weekly applications in 29 patients mainly because of mucosal toxicity with a median dose intensity of 160 mg/m2 (0-200) of cisplatin in 5.5 weeks.
  • The median overall and relapse-free survival times were 36 and 31 months, respectively.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Cisplatin / therapeutic use. Hypopharyngeal Neoplasms / therapy. Oropharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Dose Fractionation. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Prospective Studies. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc.
  • (PMID = 15459918.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Tsou YA, Hua JH, Lin MH, Tsai MH: Analysis of prognostic factors of chemoradiation therapy for advanced hypopharyngeal cancer--does tumor volume correlate with central necrosis and tumor pathology? ORL J Otorhinolaryngol Relat Spec; 2006;68(4):206-12
Genetic Alliance. consumer health - Hypopharyngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors of chemoradiation therapy for advanced hypopharyngeal cancer--does tumor volume correlate with central necrosis and tumor pathology?
  • OBJECTIVES: Not all patients with hypopharyngeal cancer who undergo concurrent chemoradiation therapy have a good prognosis.
  • We hope to find the significant prognostic factors that could help us in patient selection for concurrent chemoradiation therapy.
  • STUDY DESIGN: We used a retrospective analysis on several prognostic factors which may affect the treatment outcome and prognosis.
  • METHODS: We studied 51 patients with stage III-IV hypopharyngeal cancer who underwent chemoradiation therapy as the first treatment method.
  • Possible significant prognostic factors (i.e. tumor volume, central necrosis, pathology, age) were collected to determine whether they correlate with local disease control and survival.
  • RESULTS: Primary tumor volume correlated with local disease control and survival.
  • The greatest risk for local failure was found among patients with primary tumor volumes >19.0 ml (p = 0.001).
  • The survival rate among patients with primary tumor volumes >19.0 ml was only 39.3% compared with 78.3% for patients with volumes <19.0 ml (p = 0.036).
  • A proportional hazard model indicated that significant parameters associated with overall survival were primary tumor volume (p = 0.036) and central necrosis (p = 0.008).
  • According to the cancer cell differentiation, the hazard risk in the well-differentiated group was 5.62 folds higher than in the poorly differentiated group (p = 0.05).
  • Patients with an initial complete response had a primary tumor volume <19 ml (p = 0.001, 0.016), poorly differentiated pathology (p = 0.001, 0.016), and no central necrosis (p = 0.001, 0.016).
  • Other relatively poor significant factors were T stage above III (p = 0.047), cervical lymphadenopathy beyond level II (p = 0.046), and a nodal volume >10.0 ml (p = 0.029).
  • N stage, age and gender were not significant prognostic factors.
  • CONCLUSION: Tumor volume is the most important prognostic factor of treatment outcome for patients with hypopharyngeal cancer and should always be taken into consideration in treatment planning.
  • Other possible prognostic factors which affect the initial complete response rate and survival rate including central necrosis, pathology, nodal number and nodal volume, T stage above III, and cervical lymphadenopathy beyond level II have a relatively low correlation with treatment outcome.
  • In our study, there was a correlation between tumor volume and central necrosis, but no significant correlation between pathological differentiation and tumor volume, although both affect treatment outcome.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Logistic Models. Lymph Nodes / pathology. Male. Middle Aged. Necrosis. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 16508339.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


30. Urba SG, Moon J, Giri PG, Adelstein DJ, Hanna E, Yoo GH, Leblanc M, Ensley JF, Schuller DE: Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J Clin Oncol; 2005 Jan 1;23(1):88-95
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial.
  • PURPOSE: The Southwest Oncology Group designed a phase II trial for patients with base of tongue or hypopharyngeal cancer to evaluate the complete histologic response rate at the primary site after induction chemotherapy followed by chemoradiotherapy for responders.
  • PATIENTS AND METHODS: Fifty-nine eligible patients were enrolled; 37 had base of tongue cancer, and 22 had hypopharynx cancer.
  • Forty-two percent had stage III disease, and 58% had stage IV disease.
  • Induction chemotherapy was two cycles of cisplatin 100 mg/m(2) and fluorouracil 1,000 mg/m(2)/d for 5 days.
  • RESULTS: Forty-five patients (76%) had a greater than 50% response at the primary after induction chemotherapy; 43 went on to receive definitive chemoradiotherapy.
  • Seventy-five percent of patients did not require surgery at the primary tumor site.
  • CONCLUSION: Patients with base of tongue or hypopharyngeal cancer treated with this regimen of induction chemotherapy followed by definitive chemoradiotherapy have a good rate of organ preservation without compromise of survival.
  • [MeSH-major] Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / therapy. Tongue Neoplasms / pathology. Tongue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Radiotherapy Dosage. Salvage Therapy

  • Genetic Alliance. consumer health - Tongue cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15625363.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03096; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA58416; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA74647
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Ghaffar S, Akhtar S, Ikram M, Imam SZ, Sepah YJ: Comparison of different treatment modalities in advanced laryngeal hypopharyngeal squamous cell carcinoma. J Coll Physicians Surg Pak; 2010 Mar;20(3):171-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of different treatment modalities in advanced laryngeal hypopharyngeal squamous cell carcinoma.
  • OBJECTIVE: To compare outcome of patients with advanced laryngeal hypopharyngeal squamous cell carcinoma treated surgically or with chemotherapy and/or radiotherapy.
  • METHODOLOGY: Medical records of already treated stage-III and IV squamous cell carcinoma of larynx/hypopharynx patients were reviewed.
  • Group-A comprised of patients treated with surgery +/- adjuvant therapy whereas non-surgically managed patients were labeled as group-B.
  • Kaplan Meier technique was used to estimate mean recurrence time with standard errors.
  • RESULTS: Sixty two percent of group-A and 49% patients of group-B were stage-III.
  • In group-A, 40% patients received postoperative adjuvant therapy while in group-B, 45% received concomitant chemoradiation.
  • Mean recurrence time was 1369+193 days.
  • In group-A, mean recurrence time was 2097+277 days.
  • The hazard ratio of recurrence in hypopharyngeal tumours was 1.5 times (95% CI 0.68, 3.30) as compared to tumours of larynx.
  • The hazard ratio of recurrence was 1.98 times (95% CI 0.99, 3.95) when both larynx and hypopharynx were involved as compared to when tumour was localized to larynx only.
  • No residual disease was noted at the completion of treatment in surgical group-A while 62% patients of the group-B had residual disease at the completion of treatment.
  • CONCLUSION: Statistically significant difference was noted in disease free outcome when stage-III and IV larynx hypopharynx cancer was managed surgically as compared to non-surgical management.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20392379.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


32. Featherstone CJ, Clarke S, Jackson MA, Shannon KF, McNeil EB, Tin MM, Clifford A, O'Brien CJ: Treatment of advanced cancer of the larynx and hypopharynx with chemoradiation. ANZ J Surg; 2004 Jul;74(7):554-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced cancer of the larynx and hypopharynx with chemoradiation.
  • AIM: To analyze the outcome of patients diagnosed with advanced cancer of the larynx and hypopharynx treated with combined chemotherapy and radiotherapy at Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, Australia.
  • Outcome measures were: treatment toxicity, locoregional tumour control, and disease specific survival.
  • RESULTS: Among 54 eligible patients, cancer involved the larynx in 31 patients and hypopharynx in 23 and, of these, 38 (70%) completed all the scheduled treatment.
  • Chemotherapy and radiotherapy were given sequentially in 39 patients and concurrently in 15.
  • The median age of patients was 63 years (range 35-79 years) and all but three had clinical stage III or IV disease.
  • There were two treatment related deaths.
  • Overall, 11 (24%) patients have had a laryngectomy; five for persistent disease, three for local recurrence and three for treatment related complications in the absence of disease.
  • There were 15 cancer-related deaths.
  • Cumulative disease specific survival at 2 years was 77% for the larynx cancer group and 72% for hypopharynx.
  • CONCLUSIONS: Patients diagnosed with advanced cancer of the larynx and hypopharynx may be considered for organ preservation treatment with chemoradiation, reserving surgery for persistent or recurrent disease.
  • Careful patient selection is recommended because of the potential for significant treatment related toxicity.
  • [MeSH-major] Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15230789.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


33. Yamazaki H, Inoue T, Tanaka E, Yoshida K, Imai A, Yoshioka Y, Nakamura H, Yoshida J, Inoue T: Radiation and low dose adriamycin for the treatment of carcinoma of the hypopharynx. Anticancer Res; 2000 Nov-Dec;20(6C):4713-20
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation and low dose adriamycin for the treatment of carcinoma of the hypopharynx.
  • PURPOSE: To evaluate the utility of adriamycin in radiation therapy for hypopharyngeal cancer.
  • PATIENTS AND METHODS: Forty-five patients with hypopharyngeal carcinoma without distant metastasis were treated.
  • /once a week, median 64 mg) concurrently with radiation therapy to 38 patients, 76% (34 out of 45) of whom were in an advanced stage (III or IV).
  • Radiation therapy achieved an 84% (38 out of 45) response rate at 40 Gy.
  • Treatment without voice function loss was attained for 16 patients, consisting of 15 local CR (all T1 and 12 out of 26 T2 tumors) by radical radiation therapy and one posterior wall resection for a T2 tumor.
  • In 18 patients with T2 cancer originating from the pyriform sinus, 69% local control was obtained for patients using adriamycin compared with 20% for patients without adriamycin (p = 0.17).
  • CONCLUSIONS: Radiation therapy using low dose adriamycin with or without follow-up surgery is safe and has potential to be a good option.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Doxorubicin / therapeutic use. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Combined Modality Therapy / adverse effects. Dose-Response Relationship, Radiation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Radiotherapy / adverse effects. Survival Rate. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205206.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin
  •  go-up   go-down


34. Saarilahti K, Kajanti M, Atula T, Mäkitie A, Aaltonen LM, Kouri M, Mäntylä M: Biweekly escalated, accelerated hyperfractionated radiotherapy with concomitant single-dose mitomycin C results in a high rate of local control in advanced laryngeal and hypopharyngeal cancer. Am J Clin Oncol; 2004 Dec;27(6):589-04
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biweekly escalated, accelerated hyperfractionated radiotherapy with concomitant single-dose mitomycin C results in a high rate of local control in advanced laryngeal and hypopharyngeal cancer.
  • The purpose of this study is to evaluate the efficacy of a dose-escalated, accelerated, and hyperfractionated radiotherapy schedule with a concomitant single dose of mitomycin C in the treatment of patients with advanced laryngeal or hypopharyngeal cancer.
  • Twenty-one previously untreated patients with advanced squamous cell carcinoma (stage III, n = 6; stage IV, n = 15) were treated with a biweekly dose-escalated, accelerated, and hyperfractionated schedule up to a total dose of 74.4 Gy in 54 fractions over 5 weeks.
  • The median follow-up after treatment of surviving patients is 48 months (range, 28 to 61 months).
  • All patients showed complete tumor control at the primary site when evaluated 2 months after chemoirradiation by laryngomicroscopy or hypopharyngoscopy and radiologic imaging (CT, MRI).
  • Two laryngectomies were carried out after given therapy: 1 for residual cancer and 1 for suspected residual cancer.
  • After a median follow-up of 43 months (range, 28 to 61 months), a local control rate of 70% and disease-free survival (DFS) rate of 60% were achieved in the laryngeal cancer patients; in patients with hypopharyngeal cancer, the corresponding figures were 64% (82% after salvage surgery) and 36%.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Mitomycin / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15577437.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


35. Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, Jahnke K, Stueben G, Herrmann T, Bamberg M, Wust P, Hinkelbein W, Wernecke KD: Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol; 2005 Feb 20;23(6):1125-35
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.
  • PURPOSE: To report the results and corresponding acute and late reactions of a prospective, randomized, clinical study in locally advanced head and neck cancer comparing concurrent fluorouracil (FU) and mitomycin (MMC) chemotherapy and hyperfractionated accelerated radiation therapy (C-HART; 70.6 Gy) to hyperfractionated accelerated radiation therapy alone (HART; 77.6 Gy).
  • PATIENTS AND METHODS: Three hundred eighty-four stage III (6%) and IV (94%) oropharyngeal (59.4%), hypopharyngeal (32.3%), and oral cavity (8.3%) cancer patients were randomly assigned to receive either 30 Gy (2 Gy every day) followed by 1.4 Gy bid to a total of 70.6 Gy concurrently with FU (600 mg/m(2), 120 hours continuous infusion) days 1 through 5 and MMC (10 mg/m(2)) on days 5 and 36 (C-HART) or 14 Gy (2 Gy every day) followed by 1.4 Gy bid to a total dose of 77.6 Gy (HART).
  • CONCLUSION: C-HART (70.6 Gy) is superior to dose-escalated HART (77.6 Gy) with comparable or less acute reactions and equivalent late reactions, indicating an improvement of the therapeutic ratio.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Fluorouracil / administration & dosage. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Mitomycin / administration & dosage
  • [MeSH-minor] Actuarial Analysis. Adult. Aged. Combined Modality Therapy. Dose Fractionation. Female. Germany. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Patient Compliance. Prospective Studies. Radiotherapy / adverse effects. Radiotherapy Dosage. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15718308.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


36. El-Deiry M, Funk GF, Nalwa S, Karnell LH, Smith RB, Buatti JM, Hoffman HT, Clamon GH, Graham SM, Trask DK, Dornfeld KJ, Yao M: Long-term quality of life for surgical and nonsurgical treatment of head and neck cancer. Arch Otolaryngol Head Neck Surg; 2005 Oct;131(10):879-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term quality of life for surgical and nonsurgical treatment of head and neck cancer.
  • OBJECTIVE: To compare the long-term, health-related quality-of-life outcomes in patients with advanced head and neck cancer (HNC) treated with surgery and postoperative radiation therapy (SRT) or concurrent chemotherapy and radiation therapy (CRT).
  • DESIGN: Matched-pair study comparing patients with advanced HNC treated with SRT or CRT at least 12 months after treatment.
  • PATIENTS: Patients with stage III or IV squamous cell carcinoma of the oropharynx, hypopharynx, and larynx who underwent SRT or received CRT.
  • MAIN OUTCOME MEASURES: Head and neck cancer-specific health-related quality of life from the Head and Neck Cancer Inventory and level of depressive symptoms from the Beck Depression Inventory.
  • RESULTS: The matching process resulted in 27 patients in each treatment group.
  • [MeSH-minor] Combined Modality Therapy. Female. Health Status Indicators. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Male. Middle Aged. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Speech, Alaryngeal

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16230590.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA106908-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


37. Carvalho AL, Salvajoli JV, Kowalski LP: A comparison of radiotherapy or radiochemotherapy with symptomatic treatment alone in patients with advanced head and neck carcinomas. Eur Arch Otorhinolaryngol; 2000;257(3):164-7
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of radiotherapy or radiochemotherapy with symptomatic treatment alone in patients with advanced head and neck carcinomas.
  • The choice of palliative treatment and the prognostic factors in unresectable head and neck cancer cases continue to be controversial.
  • In the present study we compared the survival rates of untreated stage IV head and neck cancer patients with cases managed prospectively at A.C.
  • Camargo Hospital for Cancer with neoadjuvant chemotherapy, concomitant chemotherapy or radiotherapy alone.
  • Previous results had shown that while the type of treatment did not influence survival rates (P = 0.706), tumor response to treatment (whether complete, partial or none) significantly influenced survival (P = 0.00002).
  • In the present study we compared the survival rates in the groups with untreated patients (who remained untreated until death) with the same demographic and clinical characteristics of patients receiving treatment.
  • We found that there was a significant difference between the survival rates of the untreated group and those of the treated groups that was independent of the type of treatment performed (P < 0.00001) or the tumor response to treatment (P < 0.0001).
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Neoadjuvant Therapy. Oropharyngeal Neoplasms / drug therapy. Palliative Care
  • [MeSH-minor] Combined Modality Therapy. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Prospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10839492.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] GERMANY
  •  go-up   go-down


38. Lambert L, Fortin B, Soulières D, Guertin L, Coulombe G, Charpentier D, Tabet JC, Bélair M, Khaouam N, Nguyen-Tan PF: Organ preservation with concurrent chemoradiation for advanced laryngeal cancer: are we succeeding? Int J Radiat Oncol Biol Phys; 2010 Feb 1;76(2):398-402
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation with concurrent chemoradiation for advanced laryngeal cancer: are we succeeding?
  • PURPOSE: To determine the rates of organ preservation and function in patients with advanced laryngeal and hypopharyngeal carcinomas treated with concurrent chemoradiotherapy (CRT).
  • METHODS AND MATERIALS: Between April 1999 and September 2005, 82 patients with advanced laryngeal (67%) and hypopharyngeal carcinomas (33%) underwent conventional radiotherapy and concurrent platinum-based chemotherapy with curative intent.
  • Eighteen patients (22%) were in Stage III and 64 (78%) were in Stage IV.
  • The median radiation dose was 70 Gy.
  • CONCLUSIONS: In our institution, CRT for advanced hypopharyngeal and laryngeal carcinoma has provided good overall survival and locoregional control in the majority of patients, but a significant proportion did not benefit from this approach because of either locoregional failure or late complications.
  • [MeSH-major] Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Combined Modality Therapy / mortality. Disease-Free Survival. Female. Gastrostomy / utilization. Humans. Male. Middle Aged. Radiotherapy Dosage. Tracheostomy / utilization

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19394155.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


39. Kazi R, Venkitaraman R, Johnson C, Prasad V, Clarke P, Rhys-Evans P, Nutting CM, Harrington KJ: Electroglottographic comparison of voice outcomes in patients with advanced laryngopharyngeal cancer treated by chemoradiotherapy or total laryngectomy. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):344-52
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electroglottographic comparison of voice outcomes in patients with advanced laryngopharyngeal cancer treated by chemoradiotherapy or total laryngectomy.
  • PATIENTS AND METHODS: Twenty-one patients (19 male, 2 female, median age [range] 65 [50-85] years) with Stage III/IV laryngopharyngeal cancer received induction chemotherapy followed by radical chemoradiotherapy.
  • Electroglottography, using the sustained vowel /i/ and connected speech, was performed before treatment and 1, 6, and 12 months after treatment.
  • RESULTS: Before treatment the vocal measures for the chemoradiotherapy patients were significantly different from normal controls in jitter (p = 0.02), maximum phonation time (MPT) (p = 0.001), and words per minute (WPM) (p = 0.01).
  • At 12 months after treatment MPT and WPM had normalized, but jitter and normalized noise energy were significantly worse than in normal controls.
  • Comparison of voice outcomes at 12 months for chemoradiotherapy patients revealed superiority over the TL group in all parameters except MPT (18.2 s vs. 10.4 s, p = 0.06).
  • Analysis of the recovery of voice up to 12 months after treatment revealed progressive improvement in most electroglottographic measures.
  • [MeSH-major] Electric Impedance. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Laryngectomy / methods. Voice Quality / physiology
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Glottis / physiopathology. Humans. Male. Middle Aged. Prospective Studies. Speech Intelligibility / drug effects. Speech Intelligibility / radiation effects. Statistics, Nonparametric. Time Factors. Voice Disorders / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17881146.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


40. Ackerstaff AH, Balm AJ, Rasch CR, de Boer JP, Wiggenraad R, Rietveld DH, Gregor RT, Kröger R, Hilgers FJ: First-year quality of life assessment of an intra-arterial (RADPLAT) versus intravenous chemoradiation phase III trial. Head Neck; 2009 Jan;31(1):77-84
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We report the results of a multicenter randomized phase III study, assessing quality of life (QOL) in intra-arterial (IA) versus standard intravenous (IV) chemoradiation in advanced head and neck cancer.
  • METHODS: Two hundred seven patients with inoperable stage IV disease-152 men and 55 women; mean age, 55 years-were included in this study.
  • The patients were treated with standard radiotherapy with 4 weekly IA or 3 weekly IV cisplatin infusions.
  • RESULTS: Overall QOL deteriorated in all patients during treatment, is gradually improving over 1 year.
  • IV patients were significantly more fatigued (p <.006).
  • CONCLUSION: During treatment, significantly fewer problems with nausea and vomiting occurred in IA than in IV patients.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Head and Neck Neoplasms / drug therapy. Infusions, Intra-Arterial. Infusions, Intravenous. Quality of Life
  • [MeSH-minor] Alcohol Drinking / epidemiology. Combined Modality Therapy. Fatigue / epidemiology. Female. Health Behavior. Health Status Indicators. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / radiotherapy. Male. Middle Aged. Mouth Neoplasms / drug therapy. Mouth Neoplasms / pathology. Mouth Neoplasms / radiotherapy. Multivariate Analysis. Nausea / epidemiology. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / radiotherapy. Smoking / epidemiology. Surveys and Questionnaires. Vomiting / epidemiology. Xerostomia / epidemiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc. Head Neck, 2009.
  • (PMID = 18972429.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


41. Grecula JC, Schuller DE, Smith R, Rhoades CA, Nag S, Bauer CJ, Agrawal A, Au JL, Young D, Gahbauer RA: Long-term follow-up on an intensified treatment regimen for advanced resectable head and neck squamous cell carcinomas. Cancer Invest; 2001;19(2):127-36
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up on an intensified treatment regimen for advanced resectable head and neck squamous cell carcinomas.
  • From February 1993 through July 1994, 37 patients with stage III-IV squamous cell carcinomas of the oral cavity, oropharynx, or hypopharynx (stage II-IV) were registered to a treatment regimen consisting of preoperative continuous infusion cisplatin (80 mg/m2/80 hours) with hyperfractionated external beam radiotherapy (9.1 Gy/7 fractions of 1.3 Gy BID), surgical resection, intraoperative radiotherapy (7.5 Gy), and postoperative radiotherapy (40 Gy) with concurrent cisplatin (100 mg/m2 x 2 courses).
  • The objectives of the regimen were to improve patient compliance while also increasing treatment intensity.
  • The purpose of this article is to report the local, regional (nodal), and distant disease control of these patients after an extended time at risk (median 40 months).
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Cisplatin / therapeutic use. Head and Neck Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant / adverse effects. Combined Modality Therapy / adverse effects. Dose Fractionation. Follow-Up Studies. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy. Mouth Neoplasms / surgery. Neoplasm Metastasis. Neoplasm Staging. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Patient Compliance. Radiotherapy Dosage. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Invest. 2001;19(2):217-8 [11296625.001]
  • (PMID = 11296617.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30CA16058
  • [Publication-type] Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement